Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research on the FDA’s ongoing investigation into valsartan and ARB class impurities and the agency’s steps to address the root causes of the safety issues - FDA Press Releases

FDA describes the ongoing investigation into the ARB class impurities and agency’s steps to address the root causes of the safety issues

from Food and Drug Administration--Press Releases http://bit.ly/2RMadDS
via IFTTT